openPR Logo
Press release

Consumers Ask California Appellate Court to Reconsider Cipro Anticompetitive Reverse Payment Agreements

05-21-2010 11:22 AM CET | Politics, Law & Society

Press release from: Zwerling, Schachter & Zwerling, LLP

/ PR Agency: Androvett Legal Media
Cipro users forced to overpay for medications because Bayer and Barr Laboratories agreed to keep generic equivalent from marketplace, filing states

SAN DIEGO – Attorneys representing plaintiffs who overpaid for the antibiotic Cipro are asking a California appellate court to reverse a lower court ruling that set aside antitrust claims against Bayer Corporation. The case involves the agreement Bayer made with generic competitors to prevent competition and to maintain Cipro prices at high levels. The plaintiffs are a certified class of California consumers, union health and welfare funds, and others.

In their brief, filed late last week with the California Court of Appeal for the Fourth Appellate District in San Diego, the attorneys ask the Court to allow a jury to determine whether a patent holder violates California antitrust laws by paying its generic competitors hundreds of millions of dollars not to compete.

That’s what happened between 1997 and 2004 when Bayer, with U.S. headquarters in Pittsburgh, Pa., signed an exclusionary reverse payment agreement with Montvale, N.J.-based Barr Laboratories, under which Barr agreed not to produce its generic version of Cipro. In exchange, Bayer paid Barr and other generic drug manufacturers $398.1 million, preserving Cipro as the only choice for consumers and thereby maintaining, even increasing, its cost.

While the patent on Cipro expired in 2004, attorneys representing consumers and third-party payers argue that those groups paid far more for the drug than they should have. They’re asking the California appellate court to set aside a summary judgment granted by a lower court in Bayer’s and Barr’s favor last year.

In that ruling, California Superior Court Judge Richard E.L. Strauss adopted the standard set forth in a decision by the U.S. Court of Appeals for the 2nd Circuit in a reverse payment case involving the drug Tamoxifen. However, a panel of judges ruling in a separate Cipro case at the 2nd Circuit recently identified “compelling reasons” to reconsider the Tamoxifen case, and went so far as to invite the Cipro plaintiffs to petition for a hearing of the entire court to address “the important interests identified.”

In addition, the Obama Administration; members of Congress; the Federal Trade Commission; the Department of Justice, state attorneys general, including the Attorney General of California; public interest groups; scholars and medical professionals are on record saying these exclusionary reverse payment agreements are wrong.

“The whole point of having generic drugs is to lower health care costs, including the money consumers pay for badly needed medications,” says attorney Dan Drachler of Zwerling, Schachter & Zwerling, LLP, who represents the plaintiffs along with attorney Joseph Saveri of Lieff Cabraser Heimann & Bernstein, LLP. “The agreements between Bayer and the other companies avoided the law, kept prices high and protected unreasonable profits for the drug manufacturers - profits paid for by everyone who bought the drug. If we truly are concerned about the high cost of health care in this country, courts must enforce the antitrust laws and prohibit exclusionary reverse payment agreements.”

With offices in New York City, Garden City, N.Y., and Seattle, Zwerling, Schachter & Zwerling, LLP attorneys play a leading role in numerous major securities cases, complex commercial litigation and antitrust matters pending in federal and state courts across the nation. The firm has been recognized by courts throughout the country as highly experienced and skilled in complex litigation, particularly with respect to federal securities class-action litigation.

More information is available at http://www.zsz.com.

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York and Nashville, Tenn., is among the largest law firms in the United States that represents plaintiffs only. The firm has a comprehensive practice which includes antitrust, dangerous or defective products, environmental damage, and employment discrimination. The firm has a national reputation for professional integrity and the efficient and responsible prosecution of its clients’ claims.

More information is available at http://www.lieffcabraser.com.

For more information about the appeal in the California Cipro class-action case, please contact Mark Annick at 800-559-4534 (office), 214-213-1754 (mobile) or mark@androvett.com.

With offices in New York City, Garden City, N.Y., and Seattle, Zwerling, Schachter & Zwerling, LLP attorneys play a leading role in numerous major securities cases, complex commercial litigation and antitrust matters pending in federal and state courts across the nation. The firm has been recognized by courts throughout the country as highly experienced and skilled in complex litigation, particularly with respect to federal securities class-action litigation.

More information is available at http://www.zsz.com.

Zwerling, Schachter & Zwerling, LLP
Contact: Mark Annick
Androvett Legal Media
2501 Oak Lawn Avenue
Suite 650
Dallas, TX 75219
214-559-4630
mark@androvett.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Consumers Ask California Appellate Court to Reconsider Cipro Anticompetitive Reverse Payment Agreements here

News-ID: 132472 • Views: 1371

More Releases from Zwerling, Schachter & Zwerling, LLP

Appeals Court Clears Way for Century 21 Class-Action Lawsuit
TRENTON, N.J. – A class-action lawsuit filed by Century 21 franchisees against Century 21 Real Estate Corp. and parent company Cendant is moving forward following a decision of the New Jersey Appellate Division. In August, New Jersey Superior Court Judge Robert J. Brennan certified a class of current and former Century 21 franchisees in a lawsuit alleging breach of contract and other claims against their franchisor, Century 21 Real Estate Corp.,
New York Law Firm Zwerling, Schachter & Zwerling to Pursue Securities Fraud Clai …
NEW YORK – The New York law firm of Zwerling, Schachter & Zwerling, LLP, has been retained by clients to pursue potential claims of securities fraud involving Dallas-based Provident Royalties, LLC. On July 7, 2009, the U.S. Securities and Exchange Commission filed suit against Provident Royalties and its three principals alleging securities fraud. Paul "Russ" Melbye, Brendan Coughlin and Henry Harrison are accused of engaging in a classic Ponzi scheme
Securities Fraud Law Firm Zwerling, Schachter & Zwerling Representing Madoff Fra …
Attorney Robert S. Schachter says Bank Medici and Bank Austria Implicated in Madoff Fallout NEW YORK – An international probe by the law firm Zwerling, Schachter & Zwerling is focusing on whether major Austrian banks used financial funds in Europe to fraudulently funnel billions into Bernard L. Madoff’s bogus investment enterprises, resulting in billions in losses for European parties. The New York-based law firm already is working with nearly a dozen individuals,
New York Law Firm Zwerling, Schachter & Zwerling, LLP Investigating “Feeder Fu …
NEW YORK – The New York law firm of Zwerling, Schachter & Zwerling, LLP, has been retained by clients that have asked the firm to investigate so-called “feeder funds” that helped deliver billions of dollars to investment adviser Bernard L. Madoff before the recent collapse of his investment businesses. Reports indicate Madoff has admitted to operating what amounted to a $50 billion Ponzi scheme. Feeder funds, such as the Fairfield Sentry Fund,

All 5 Releases


More Releases for Cipro

Asymptomatic Bacteriuria Treatment Market : Global Forecast over 2028 | Apotex I …
Asymptomatic bacteriuria is defined as the isolation of a substantial count of bacteria in voided urine specimen obtained from an individual who does not show any symptoms and signs of urinary tract infection. It is caused by bacterial colonization inside the urinary tract, which affects around 5 to 10 percent of both pregnant and sexually active women. However, asymptomatic bacteriuria is less prevalent in men as compared to women. Asymptomatic
Asymptomatic Bacteriuria Treatment Market – Evolution Survey 2028 | Ranbaxy La …
Asymptomatic bacteriuria is defined as the isolation of a substantial count of bacteria in voided urine specimen obtained from an individual who does not show any symptoms and signs of urinary tract infection. It is caused by bacterial colonization inside the urinary tract, which affects around 5 to 10 percent of both pregnant and sexually active women. However, asymptomatic bacteriuria is less prevalent in men as compared to women. Asymptomatic
Quinolones Market Key Manufacturers, Development Trends and Competitive Analysis …
Antibacterial drugs are classified into β-lactams, macrolides, tetracyclines, aminoglycosides, sulfonamides, phenicols, quinolones, and miscellaneous antibacterial drugs. Quinolones is a major class of antibacterial drugs. Quinolones/fluoroquinolones are synthetic antibacterial drugs that exhibit a specific function of inhibiting the nucleic acid synthesis. Depending on their bactericidal properties, quinolones are effective against bacterial infections of the skin, the sinuses, the lungs, the stomach, and the urinary tract. With their property of inhibiting the
Quinolones Market - Global Industry Analysis, Size, Share, Growth, Trends and Fo …
Researchmoz added Most up-to-date research on "Quinolones Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025" to its huge collection of research reports. Antibacterial drugs are classified into ?-lactams, macrolides, tetracyclines, aminoglycosides, sulfonamides, phenicols, quinolones, and miscellaneous antibacterial drugs. Quinolones is a major class of antibacterial drugs. Quinolones/fluoroquinolones are synthetic antibacterial drugs that exhibit a specific function of inhibiting the nucleic acid synthesis. Depending on their
Quinolones Market Detailed Study Analysis with Forecast by 2025
Antibacterial drugs are classified into β-lactams, macrolides, tetracyclines, aminoglycosides, sulfonamides, phenicols, quinolones, and miscellaneous antibacterial drugs. Quinolones is a major class of antibacterial drugs. Quinolones/fluoroquinolones are synthetic antibacterial drugs that exhibit a specific function of inhibiting the nucleic acid synthesis. Depending on their bactericidal properties, quinolones are effective against bacterial infections of the skin, the sinuses, the lungs, the stomach, and the urinary tract. With their property of inhibiting the
Skiermont Puckett LLP Launches Innovative Law Practice
DALLAS – Veteran courtroom lawyers Paul Skiermont and Donald Puckett are pleased to announce the formation of their new Dallas-based national law practice. Skiermont Puckett LLP is dedicated to representing plaintiffs and defendants in patent infringement, antitrust and other complex commercial litigation. The firm will employ an innovative law firm model by relying exclusively on alternative fee arrangements in which clients are not billed at an hourly rate. Instead,